Skip to main content

Transgenomic s Lender Laurus Converts $650,000 in Debt into Stock

NEW YORK, March 31 (GenomeWeb News) - Laurus Master Fund has converted into stock an additional $650,000 of a secured convertable term note, the company said in an SEC filing -- the second debt-to-equity conversion with the bank in one week.

 

The original note was issued in the principal amount of $2.8 million, and the debt-to-equity conversion equated to 1.25 million shares. The first conversion, announced on March 18, equated to $1.8 million of the outstanding debt, and 10 percent of the Transgenomic's market capitalization.

 

 on a $7.5 million revolving credit facility. Mitchell Murphy, Transgenomic's interim-CFO, told GenomeWeb News that this amount translated into approximately 10 percent of the company's current market capitalization.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.